Insulin-like growth factor-1 (IGF-1), a known activator of PI3K signaling [49], was used to further investigate the ability of Sirt6 to modify PI3K signaling in DLBCL cells. This evidence concerns the gene IGF1 and diffuse large B-cell lymphoma.